JCJ and MA contributed equally to this report.
M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy
Version of Record online: 11 JAN 2012
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology
Clinical & Experimental Immunology
Volume 167, Issue 2, pages 303–308, February 2012
How to Cite
Ameye, L., Paesmans, M., Thiel, S., Jensenius, J. C. and Aoun, M. (2012), M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy. Clinical & Experimental Immunology, 167: 303–308. doi: 10.1111/j.1365-2249.2011.04512.x
- Issue online: 11 JAN 2012
- Version of Record online: 11 JAN 2012
- Accepted manuscript online: 28 OCT 2011 06:49AM EST
- Accepted for publication 21 October 2011
- chemotherapy infections;
- mannan-binding lectin;
- pattern recognition molecules
The pattern recognition molecules H-ficolin, L-ficolin and M-ficolin bind to micro-organisms. They activate the lectin pathway of complement through mannan-binding lectin (MBL)-associated serine proteases (MASPs). Association between low MBL levels and infections in patients undergoing chemotherapy for haematological diseases has been observed previously. We now examine for MASP-2, MASP-3 and ficolin levels. We assessed the concentration of lectin pathway molecules as risk factors for infection in patients with haematological malignancy undergoing chemotherapy. Samples taken before the initiation of chemotherapy covering 117 chemotherapy cycles in 105 patients were available. MASPs and ficolins were measured by time-resolved immunoflourometric assays and the levels related to parameters of infections. End-points included febrile neutropenia, documented infections, bacteraemia or severe infections. Lower M-ficolin concentrations were found in patients who developed a severe infection: median 0·27 µg/ml compared to 0·47 µg/ml in patients who did not develop a severe infection (P = 0·01). Conversely, MASP-2 was higher in these patients: median 0·53 µg/ml compared to 0·37 µg/ml, respectively (P = 0·008). When considering M-ficolin levels below 0·36 µg/ml as deficient, the time to development of severe infection was shorter in the M-ficolin deficient group: the hazard ratio was 2·60 (95% confidence interval: 1·23–5·49). No associations were revealed between infections and H-ficolin, L-ficolin or MASP-3. Patients with low M-ficolin are more likely to develop severe infections, whereas MASP-2 showed the opposite.